Study Evaluating Antibiotic Utilization Measures and Control of Extended-Spectrum-Lactamases (ESBLs)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00254696|
Recruitment Status : Completed
First Posted : November 16, 2005
Last Update Posted : April 15, 2011
- To determine the value of using piperacillin/tazobactam in reducing the cases of ESBL producing E. coli or K. pneumoniae colonization and infection.
- To determine the acquisition rate of ESBL producing E. coli or K. pneumoniae, both pre and post intervention in the selected medical centers.
|Condition or disease||Intervention/treatment||Phase|
|Bacterial Infection||Drug: Extended-Spectrum-Lactamases (ESBLs)||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||710 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Association of Antibiotic Utilization Measures and Control of Extended-spectrum-lactamases (ESBLs)|
|Study Start Date :||June 2004|
|Actual Primary Completion Date :||March 2005|
|Actual Study Completion Date :||March 2005|
- Acquisition rate of ESBL producing E. coli or K. pneumoniae at the end of phase I (pre-intervention) and phase II (last 3 months)
- Infection rate of ESBL producing E. coli or K. Pneumoniae at the end of phase I (pre-intervention) and phase II (last 3 months)
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00254696
|Study Director:||Medical Monitor||Wyeth is now a wholly owned subsidiary of Pfizer|
|Principal Investigator:||Trial Manager||For China firstname.lastname@example.org|